Portola Pharmac (PTLA) Misses Q1 EPS by 3c

Portola Pharmac (NASDAQ: PTLA) reported Q1 EPS of ($0.75), $0.03 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.81 million.

For earnings history and earnings-related data on Portola Pharmac (PTLA) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Morgan Stanley Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Equalweight
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue